海外の治験の状況「1」での検索結果
2039件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- Estudio de extension abierto, de 48 semanas de duracion, para evaluar la administracion de elvucitabina en combinacion con agentes antirretrovirales de base en sujetos que hayan completado 14 dias de tratamiento en el protocolo ACH443-014A. (An open-label, 48-week extension study of elvucitabine administered in combination with background antiretroviral agents in subjects who have completed 14 days of treatment in Protocol ACH443-014A.)
- Infección crónica causada por el virus de inmunodeficiencia humana (VIH-1) ("Chronic Human Immunodeficiency Virus (HIV-1) Infection") MedDRA version: 9.1 Level: LLT Classification code 10008919 Term: Chronic HIV infection
- Germany, Spain
- 2007-04-23
Authorised
- RANDOMISED PILOT TRIAL OF MYFORTIC FOR THE TREATMENT OF PRIMARY PROTEINURIC GLOMERULONEPHRITIS. - GloMY - Proteinuria in glomerulonephritis : Myfortic
- Primary Proteinuric Glomeruolnephritis Focal segmental glomeruloscerosis and IgA nephropathy br>MedDRA version: 14.1 Level: PT Classification code 10067757 Term: Focal segmental glomerulosclerosis System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1 Level: PT Classification code 10021263 Term: IgA nephropathy System Organ Class: 10038359 - Renal and urinary disorders
- United Kingdom
- 2010-03-17
Authorised
- Sclérose Latérale Amyotrophique (SLA) – toxine botulinique A (Botox®)
- Sclérose Latérale Amyotrophique (SLA) MedDRA version: 14.0 Level: PT Classification code 10002026 Term: Amyotrophic lateral sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- France
- 2011-09-06
Authorised
- A Clinical Trial to Examine the Effects of the Drug Atacicept in Patients with Nephropathy (Diabetic Kidney Disease).
- IgA Nephropathy br>MedDRA version: 20.1 Level: PT Classification code 10061835 Term: Diabetic nephropathy System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 20.0 Level: PT Classification code 10021263 Term: IgA nephropathy System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]
- Belgium, Czech Republic, France, Israel, Italy, Japan, Korea, Republic of, Singapore, Spain, Taiwan, United Kingdom, United States
- 2017-01-27
Authorised
- A controlled, double-blind and randomized study, to compare the immunogenicity and safety of HEXAVAC manufactured by an upgraded process to HEXAVAC manufactured by the current process when given to healthy infants at 2, 4 & 6 months of age followed by a booster dose at 12 months of age
- The vaccine is indicated for primary and booster vaccination of children against six infectious diseases: diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis caused by 3 types of poliovirus (type 1,2 and 3), and invasive infections caused by Haemophilus influenza type b.
- Czech Republic, Slovakia
- 2005-07-13
Authorised
- Change from infliximab to adalimumab in patients with Crohn’s disease in remission on infliximab: a randomized comparative case control study. - Infliximab to adalimumab switch trial
- Luminal Crohns Disease, moderate to severe, refractory to steroids and/or antimetabolitets and controlled with anti-TNF therapy MedDRA version: 8.1 Level: LLT Classification code 10011401 Term: Crohn's disease
- Belgium
- 2006-12-19
Authorised
- "Ensayo clínico controlado randomizado sobre el tratamiento precoz con insulina en recién nacidos de muy bajo peso" - NIRTURE
- Very low birth weight infants requiring intensive care have relative insulin deficiency often leading to hyperglycaemia during the first week of life. There is increasing evidence that the early postnatal period is critical for pancreatic development. This has implications both in terms of acute glucose control but also relative insulin deficiency is likely to play a role in poor postnatal growth, which has been associated with later motor and cognitive impairment.
- Spain
- 2006-02-20
Authorised
- Metformin-Wirkung am Ovar bei PCOS (MAO-Studie) - eine Pilotstudie
- Polycystic ovary syndrome is one of the most common endocrine disorders, affecting approximately 10% of women of reproductive age, associated with hyperandrogenaemia and menstrual dysfunction. The aim of the study is to examine the effects of the insulin sensitizing drug metformin on ovarian function and ovulation rate in women with PCOS. MedDRA version: 9.1 Level: LLT Classification code 10014695 Term: Endocrine disorder
- Austria
- 2007-02-07
Authorised
- Ensayo clínico multicéntrico, comparativo, doble ciego, paralelo de dos vías, de los efectos del tratamiento con cutículas de semillas de Plantago Ovata sobre el perfil lipídico de pacientes afectos de hipercolesterolemia - Plantago Ovata en Hiperlipemia
- Pacientes diagnosticados de hipercolesterolemia, con un colesterol LDL superior o igual a 130 mg/dl e inferior o igual a 189 mg/dl. Con dos factores de riesgo cardiovascular. MedDRA version: 7.1 Level: LLT Classification code 10020661
- Spain
- 2005-12-07
Authorised
- Estudio piloto de la eficacia de las estatinas en el tratamiento de la enfermedad pulmonar obstructiva crónica. (Pilot study on the efficacy of statins for the treatment of Chronic Obstructive Pulmonary Disease).
- Evaluar en la EPOC estable el efecto de la simvastatina sobre: (1) la función endotelial; (2) la inflamación pulmonar y sistémica; y, (3) el índice BODE (B: masa corporal, O: obstrucción bronquial, D: disnea y, E: tolerancia al ejercicio). (To investigate the efficacy of simvastatin in patients with COPD on: (1) pulmonary and systemic inflammation; (2) endothelial function; and, (3) BODE (B: body mass index, O: bronchial obstruction, D: dyspnea and, E: exercise tolerance) index).
- Spain
- 2008-11-10
Authorised
- Vitamin D supplementation for prevention of placenta mediated pregnancy complications. - Prevention of pregnancy complications with vitamin D
- We will try to prevent preeclampsia, groth restriction and prematurity by vitamin D supplementation given as one dose in mid pregnancy MedDRA version: 12.1 Level: LLT Classification code 10036485 Term: Pre-eclampsia MedDRA version: 12.1 Level: LLT Classification code 10036590 Term: Premature baby MedDRA version: 12.1 Level: LLT Classification code 10053759 Term: Growth retardation
- Sweden
- 2010-06-04
Authorised
- A double-blind, placebo-controlled Clinical Trial to evaluate the Safety and Efficacy of JNJ-64304500 in patients with Moderately to Severely Active Crohn’s Disease
- Active Crohn's Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Belgium, Bulgaria, Canada, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Poland, Romania, Russian Federation, Ukraine, United Kingdom, United States
- 2016-07-07
Authorised
- Same as above
- Autosomal Dominant Polycystic Kidney DIsease br>MedDRA version: 20.0 Level: LLT Classification code 10036045 Term: Polycystic kidney System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
- Denmark
- 2017-12-13
Authorised
- A Clinical Trial to Evaluate the Safety and Efficacy of CCX168 (Avacopan), a new drug for the treatment of a group of related conditions that cause the kidneys to malfunction, called C3 Glomerulopathy.
- C3 glomerulopathy (C3G) is characterized by evidence of alternative complement activation based on C3 deposition in the glomeruli. There are two forms of the disease: dense deposit disease (DDD, formerly called membranoproliferative glomerulonephritis [MPGN] Type II) and C3 glomerulonephritis (C3GN, formerly called idiopathic MPGN). MedDRA version: 20.0 Level: PT Classification code 10077827 Term: C3 glomerulopathy System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Belgium, Canada, Denmark, France, Germany, Ireland, Italy, Netherlands, Spain, United Kingdom, United States
- 2017-10-06
Authorised
- Prevention of preeclampsia (high blood pressure): Randomised trial of Pravastatin versus placebo
- Pre-eclampsia MedDRA version: 20.0 Level: PT Classification code 10036485 Term: Pre-eclampsia System Organ Class: 10036585 - Pregnancy, puerperium and perinatal conditions ;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
- Belgium
- 2017-06-07
Authorised
- Fixed-dose combination of rosuvastatin and valsartan for dual target achievement in patients with hypertension and hyperlipidaemia (UNIFY)
- Patients with mild to moderate essential arterial hypertension AND primary hypercholesterolemia or mixed dyslipidaemia (LDL-c 4.9 mmol/L or MedDRA version: 20.0 Level: PT Classification code 10062060 Term: Hyperlipidaemia System Organ Class: 10027433 - Metabolism and nutrition disorders MedDRA version: 20.0 Level: PT Classification code 10015488 Term: Essential hypertension System Organ Class: 10047065 - Vascular disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
- Hungary, Poland, Russian Federation, Serbia
- 2018-10-24
Authorised
- A study to compare the comfort and ease of use of 5 different treatment regimens for trans-capsaicin injection into the knee in patients with moderate to severe osteoarthritis knee-pain
- The index knee must show evidence of chronic OA with a K-L grade of 1, 2, 3 or 4. Subjects who were screen failures for the United States (US) CNTX-4975i-OA-301 or CNTX-4975i-OA-304 trials may be considered for this trial if the K-L grade of the index knee is 1-4, inclusive. MedDRA version: 20.0 Level: LLT Classification code 10023476 Term: Knee osteoarthritis System Organ Class: 100000004859 ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
- Germany, Spain, United Kingdom, United States
- 2018-09-05
Authorised
- Is treatment with the painkiller paracetamol safe in patients with spinal muscular atrophy and cerebral palsy?
- Spinal muscular atrophy type II (SMA II) Cerebral palsy (CP) MedDRA version: 20.1 Level: PT Classification code 10041582 Term: Spinal muscular atrophy System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 20.1 Level: PT Classification code 10008129 Term: Cerebral palsy System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Denmark
- 2018-07-11
Authorised
- Attempt of treatment optimization of newly diagnosed Ph/BCR-ABL positive patients with chronic myeloid leukemia (CML) in chronic phase: initially with a combination of nilotinib and interferon alpha followed by a nilotinib or interferon alpha maintenance therapy
- chronic phase CML MedDRA version: 20.0 Level: LLT Classification code 10009700 Term: CML System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Czech Republic, Germany
- 2012-05-29
Authorised
- Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy alone for Patients With Lung Cancer (POSEIDON).
- First-line patients with metastatistic non-small-cell lung cancer (NSCLC) with tumors that lack activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusions MedDRA version: 20.0 Level: LLT Classification code 10025055 Term: Lung cancer non-small cell stage IV System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Brazil, Bulgaria, China, Germany, Hong Kong, Hungary, Japan, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, South Africa, Taiwan, Thailand, Ukraine, United Kingdom, United States, Vietnam
- 2017-05-29
